QR-Code

Kidney Function Trajectories with Tolvaptan in ADPKD Patients with CKD-G5

Introduction: Improvement of estimated glomerular filtration rate (eGFR) slope has been established using tolvaptan in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). In Japan, the therapeutic dose of tolvaptan (60–120 mg/d) must be discontinued at chronic kidney disease stage G5...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Akinari Sekine, Junichi Hoshino, Toshio Mochizuki, Shinya Nakatani, Saori Nishio, Tatsuya Suwabe, Hiroki Hayashi, Hirayasu Kai, Koichi Seta, Fumihiko Hattanda, Sumi Hidaka, Kazushige Hanaoka, Mahiro Kurashige, Hiroshi Kataoka, Kiyotaka Uchiyama, Keiji Shimazu, Eiji Ishikawa, Yosuke Shimada, Haruna Kawano, Ken Tsuchiya, Shigeo Horie, Ichiei Narita, Yoshitaka Isaka, Satoru Muto
Format: Artigo
Sprache:Inglês
Veröffentlicht: Elsevier 2025-06-01
Schriftenreihe:Kidney International Reports
Schlagworte:
ADPKD
CKD G5
tolvaptan
Online-Zugang:http://www.sciencedirect.com/science/article/pii/S2468024925001639
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge